"Benitec, an Australian gene therapy biotech company, who is looking for institutional investors with expertise in the biotech space to take substantial holdings of at least 5%"
D, here is advice from a venture capitalist and some of what he says seems very familiar.
http://www.xconomy.com/san-francisco/2013/01/23/venbios-goodman-builds-an-inside-periscope-on-biotech-acquisitions/
If we think of BLT as a start-up, albeit already a public company with public investors, he says,
“A lot of companies got created [in the 90's] with the thinking, ‘If you build it they will come,’ ” Goodman says. But the flush times receded as the financial returns from many companies fell short, he says. A shakeout among life sciences venture firms followed, as IPO exits became fewer and leaner. These days, startups and their investors should be setting their sights on an acquisition by a larger pharmaceutical or biotechnology company, not an IPO, Goodman says. And to do that, they have to figure out what those larger companies want.
I am still scratching my head to know what our strategy is.
- Forums
- ASX - By Stock
- BLT
- cure for cancer ! & still 1.7 cents !
cure for cancer ! & still 1.7 cents !, page-57
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online